Skip to main content

About Bard Canada


Bard Canada Inc. (BCI) is a wholly owned subsidiary of C.R. Bard, Inc. which is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies. Over our 100 year history, C. R. Bard, Inc. has responded to the needs of clinicians, health care professionals and patients with strong, reliable, market-leading product and therapy offerings under a structure built upon product expertise and innovative technologies. Bard Canada Inc. has divisions focused on providing quality products that meet clinician and patient needs within the disease areas of Vascular Access, Peripheral Vascular, Surgery, Urology, and Biopsy.

At Bard Canada, there is a distinct focus on building collaborative relationships with our healthcare partners in an effort to positively transform the delivery of healthcare. As a company, we believe that the products and services we offer, positively impact the lives of our customers, our clinicians and most importantly, the patients we all serve. As patients make their journey through the various stages of their healthcare, Bard Canada is there – touching the lives of patients and those close to them.  Bard Canada also touches the lives of Canadians within their communities by serving charities and organizations across Canada through employee volunteer efforts.  Through our collaboration with our healthcare partners and the work we do in the community we strive in Advancing Lives and the Delivery of Healthcare in Canada.  

For more information on C. R. Bard, Inc., please visit www.crbard.com.

A Long History of Technological Innovation

1900s
1920s
1930s
1940s
1950s
1960s
1970s
1980s
1990s
2000s
2010s
Charles Russell Bard, founder of C.R. Bard

1907

Charles Russell Bard (pictured) begins U. S. distribution of a urethral catheter developed in Europe.

1923

Bard formerly incorporates his business as C. R. Bard. Inc.

John F. Willits and Edson L. Outwin

1926

Charles Russell Bard sells business to John F. Willits (pictured left), Sales Manager, and Edson L. Outwin (pictured right), Accountant, for $18,000.

Davol Rubber Company historic illustration and patent application

1934

Company begins distributing Foley catheters.

1948

Headquarters are moved from New York City to Summit, New Jersey; sales surpass the $1 million mark.

Edson L. Outwin, James Vassar, Harris Willits, and Edson S. Outwin at Canoe Brook Country Club in 1957

1957

C.R. Bard begins marketing its products in presterilized packages.

Bard

1963

Company goes public with a listing on the over-the-counter market.

Medical supply storage at BARD’s Bridgewater, NJ location and in-house sterilization operations

1964

First in-house manufacturing by Bard.

Bard Canada Incorporated with headquarters in Mississauga was formed to handle Canadian distribution.

1968

Bard stock began trading on the New York Stock Exchange for the first time.

 

 

Historical photography of Davol, Inc. location

1980

The 1980s brought another healthy growth spurt for Bard. In 1980 Bard continued to expand by purchasing Davol Inc. and Davol International from International Paper Company. This acquisition was significant as Davol manufactured Foley catheters, still Bard's single largest selling product. Bard also acquired Shield Healthcare Management Inc., Catheter Technology Corp. and the assets of Radi Medical Systems AB, all in the early 1980s.

1983

Bard Canada began selling directly to hospitals in Canada.

Bard

1991

In the early 1990s, Bard began to focus more carefully on its major markets, selling those divisions incidental to their main focus of development of single-patient-use products for diagnosis and treatment for the urological, cardiovascular, and surgical markets.

1994

Revenues exceeded $1 billion for the first time.

Bard Canada acquired Vas-Cath Inc, located in Mississauga, Ontario.


 

1998

Bard restructured globally along disease-state management lines and also made some divestments. The most significant latter move was the sale of the coronary catheter laboratory business, which included the company's angioplasty operations.

2005

Bard Canada achieved $50,000,000 in sales.

Bard

2008

Bard acquires LifeStent® (pictured) from Edwards Lifesciences which is marketed by Bard’s Peripheral Vascular Division, Tempe Arizona.

2009

Bard Canada moved to head office to Oakville, ON.

2010

In the largest acquisition to date, Bard acquires SenoRx, Inc., providing Bard leadership products across all breast biopsy and marker segments.

Medivance Arctic Sun

2011

Bard acquires Medivance, Inc., the market leader in the field of therapeutic hypothermia. Medivance's Arctic Sun® family of products provides clinicians with a powerful technology to effectively manage patient temperature in a non-invasive manner.

Lutonix transliminal angioplasty (PTA) balloon

2011

Bard acquires Lutonix, Inc., developer of a drug-coated percutaneous transluminal angioplasty (PTA) balloon. Lutonix is the first to conduct the only investigational device exemption (IDE) trial approved by the FDA using drug-coated balloons for the treatment of peripheral arterial disease.

Neomend logo

2012

Bard acquires privately-held Neomend, Inc., a leading developer and supplier of sprayable surgical sealants and anti-adhesion products.  This merger significantly expands the business opportunities for Bard surgical specialties in the Davol subsidiary.

Medafor Arista MPH hemostat

2013

Bard Acquires Medafor, Inc., a leading developer and supplier of plant based hemostatic agents. Medafor’s Arista® MPH Hemostat, is indicated as an adjunctive hemostatic agent to control bleeding when conventional means are ineffective or impractical. The acquisition expands the business opportunities for Bard’s surgical specialties in its Davol subsidiary.

BARD electrophysiology logo

2013

Bard divests Electrophysiology business and sells certain assets to Boston Scientific Corporation. 

2013

Bard acquires Rochester Medical, Inc., a leading developer and supplier of silicone urinary incontinence and urine drainage products. The merger represents a compelling strategic fit that enhances Bard’s position in the global urology homecare market.

Lutonix 035 drug coated balloon

2014

The Lutonix® 035 Drug Coated Balloon is the first FDA-Approved Drug Coated Balloon available in the U.S. for the treatment of Femoropopliteal Occlusive Disease. The Lutonix® 035 DCB is an angioplasty balloon coated with a therapeutic dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD) in the femoropopliteal arteries.

XenMatrix AB surgical graft antibacterial-coated regenerative collagen matrix

2014

XENMATRIX™ AB Surgical Graft Antibacterial-Coated Regenerative Collagen Matrix is the first antibacterial-coated, non-crosslinked porcine dermal graft proven to inhibit the graft colonization of MRSA, E. coli, and other bacteria in preclinical models.1,2  It uses a combination of well-characterized antibiotics, Rifampin and Minocycline, to offer an unmatched level of graft protection in challenging ventral hernia repair.
 
1. IMS Data, Q2 2014, 550K search, fda.gov.  
2. Preclinical data on file; results may not correlate to clinical performance.
 

2015

Bard acquires full ownership of its joint venture, Medicon, Inc., in Japan.

2016

Bard acquires Liberator Medical Holdings, Inc.  Liberator is a direct-to-consumer distributor of medical products classified as Durable Medical Equipment (DME).